The antiangiogenic effects of these agents are mainly based on blocking the vascular endothelial growth factor (VEGF) signaling pathway, one of the key mechanisms of tumorigenesis in general [13] and in the development of meningiomas in particular [14,15,16]. The gene discussed is VEGFA; the disease is meningioma.